The World Hepatitis Alliance supports campaigners and patient organisations around the world to help make a difference to the lives of the millions of people living with viral hepatitis and to prevent new infections. To find out more on what is going on in your country, use the map below to find local organisations, World Hepatitis Day initiatives and other initiatives.
You can also look at our ‘Wall of Stories’ and submit your own personal experience of living with hepatitis or find other community resources including an Online Scrapbook and our latest Newsletters. The This is hepatitis... blog features bloggers from around the world talking about their experiences with hepatitis.
New Drugs: the European Commission has approved VICTRELIS (boceprevir)
The European Commission (EC) has approved VICTRELIS (boceprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
The European Commission's Decision grants a single marketing authorisation that is valid in the 27 countries that are members of the European Union (EU), as well as unified labeling applicable to the European Economic Area members, Iceland, Liechtenstein and Norway.
"The EU approval of VICTRELIS for chronic hepatitis C genotype 1 is very exciting, because we now have a new option for patients with the hardest to treat form of the disease. With VICTRELIS, patients who have failed previous therapy or are new to treatment can significantly improve their chances of clearing the virus from their bodies compared to current standard therapy," http://bit.ly/nywy0f